Shepherd Financial Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Shepherd Financial Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$763K	Buy	5,973 +31	+0.5%	+$3.87K	0.07%	130
2025 Q4	$724K	Sell	5,942 -654	-10%	-$75K	0.07%	135
2025 Q3	$661K	Sell	6,596 -325	-5%	-$29.3K	0.06%	137
2025 Q2	$574K	Sell	6,921 -1,284	-16%	-$102K	0.06%	142
2025 Q1	$665K	Sell	8,205 -1,011	-11%	-$90.4K	0.08%	136
2024 Q4	$830K	Sell	9,216 -1,234	-12%	-$120K	0.1%	109
2024 Q3	$1.03M	Buy	10,450 +1,298	+14%	+$128K	0.12%	95
2024 Q2	$848K	Buy	9,152 +296	+3%	+$26.5K	0.11%	108
2024 Q1	$840K	Buy	8,856 +1,595	+22%	+$148K	0.11%	113
2023 Q4	$648K	Sell	7,261 -10,260	-59%	-$762K	0.09%	125
2023 Q3	$1.28M	Sell	17,521 -1,900	-10%	-$152K	0.2%	75
2023 Q2	$1.62M	Sell	19,421 -2,126	-10%	-$178K	0.25%	67
2023 Q1	$1.64M	Buy	21,547 +1,966	+10%	+$163K	0.27%	61
2022 Q4	$1.63M	Sell	19,581 -51	-0.3%	-$4.13K	0.29%	61
2022 Q3	$1.56M	Buy	19,632 +11,836	+152%	+$998K	0.3%	61
2022 Q2	$579K	Sell	7,796 -233	-3%	-$17.5K	0.11%	102
2022 Q1	$717K	Sell	8,029 -5,957	-43%	-$550K	0.13%	103
2021 Q4	$1.57M	Sell	13,986 -298	-2%	-$35.9K	0.27%	69
2021 Q3	$1.8M	Buy	14,284 +121	+0.9%	+$15.6K	0.35%	59
2021 Q2	$1.92M	Buy	14,163 +1,720	+14%	+$226K	0.36%	57
2021 Q1	$1.69M	Buy	12,443 +395	+3%	+$59.1K	0.37%	58
2020 Q4	$1.7M	Buy	12,048 +340	+3%	+$43.5K	0.39%	61
2020 Q3	$1.3M	Buy	11,708 +888	+8%	+$99.6K	0.31%	67
2020 Q2	$1.21M	Buy	10,820 +26	+0.2%	+$2.56K	0.33%	56
2020 Q1	$835K	Sell	10,794 -650	-6%	-$57.6K	0.29%	56
2019 Q4	$1.09M	Buy	11,444 +556	+5%	+$48.1K	0.25%	65
2019 Q3	$828K	Hold	10,888	–	–	0.21%	65
2019 Q2	$955K	Buy	10,888 +23	+0.2%	+$1.96K	0.18%	63
2019 Q1	$984K	Buy	10,865 +353	+3%	+$30K	0.19%	62
2018 Q4	$753K	Sell	10,512 -4,713	-31%	-$380K	0.16%	67
2018 Q3	$1.45M	Hold	15,225	–	–	0.33%	46
2018 Q2	$1.47M	Buy	15,225 +12,253	+412%	+$1.13M	0.33%	46
2018 Q1	$260K	Buy	+2,972	New	+$271K	0.06%	101

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Shepherd Financial Partners's XBI Position: Q1 2026 in Review

Shepherd Financial Partners increased its State Street SPDR S&P Biotech ETF (XBI) stake by 0.52% in Q1 2026, buying an estimated $3.87K and bringing the position to 5,973 shares worth $763K. The position accounts for 0.07% of the portfolio, ranked #130.

Shepherd Financial Partners first reported a position in XBI in Q1 2018 and has held it in 33 quarters since. The position peaked at $1.92M in Q2 2021. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Shepherd Financial Partners held 5,973 shares of State Street SPDR S&P Biotech ETF worth $763K as of Q1 2026.
Shepherd Financial Partners bought 31 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $3.87K.
State Street SPDR S&P Biotech ETF made up 0.07% of Shepherd Financial Partners's portfolio in Q1 2026, its #130 holding.
Shepherd Financial Partners first reported a position in State Street SPDR S&P Biotech ETF in Q1 2018 and has held it in 33 quarters since.
Shepherd Financial Partners's State Street SPDR S&P Biotech ETF position peaked at $1.92M in Q2 2021.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Shepherd Financial Partners's 13F filing for Q1 2026, filed 11 May 2026.